In June 2019 it was announced that Bio-Techne Corporation (NASDAQ: TECH) - with a track record of several small firm acquisitions - had reached agreement to acquire all of the stock of B-MoGen Biotechnologies Inc . B-Mogen is a four-year old University of Minnesota genome engineering startup start-up already having grown to some 20 employees. Working on the most complex gene editing problems with proprietary, cutting edge gene editing and delivery tools, B-Mogen is enabling and accelerating growth in immunotherapy treatments utilizing cutting edge gene editing and gene delivery technologies to create unique research solutions and disease models in human cell. The firm has several SBIR awards already taken and underway and has entered into strategic partnerships with biotechnology companies, completed projects for clients in academia and industry, along with having successfully licensed and developed novel intellectual property focused on genome engineering.
